A Randomized Controlled Trial of Oral CBD for the Treatment of Upper Extremity Musculoskeletal Pain

Exclusion criteria

• 1. Subject does not speak or read English fluently. 2. Subject is blind. 3. Severe cardiac, pulmonary, liver and /or renal disease, or any other major organ dysfunction. 4. Subject with a history of symptoms (e.g., dizziness, light-headedness, blurred vision, palpitations, weakness, syncope) related to a drop in blood pressure due to postural changes. 5. Coumadin use at time of screening. 6. History of mental illness. 7. Subjects who are incarcerated. 8. Subjects who satisfy any DSM-V criteria for current psychiatric illness such as bipolar disorder, depression, anxiety, schizophrenia, psychosis, substance use disorder or any other psychiatric diagnosis 9. Subjects who have used intra-articular corticosteroids 30 days prior to screening. 10. History of drug or substance abuse. 11. Pre-existing CBD product usage currently (or within the prior 3 months) using recreational or medicinal cannabis, any cannabinoid-based medications, and is unwilling to abstain for the duration of the study. 12. Subject has had a corticosteroid injection ≤ 60 days prior. 13. Subjects who are unwilling to agree to no opioid medications or topical analgesic medications during the study period. 14. Any woman of child bearing potential or male patient's partner unwilling to ensure that they or their partner use effective contraception, for example, hormonal contraception, double barrier, intra-uterine device, during the study and for females, through 30 days thereafter, and for males, three months thereafter. 15. Any male not willing to avoid donating sperm during the duration of the study treatment period and for three months thereafter. 16. Any patient with aberrant liver function as defined by either of the following:
• ALT \>5x ULN or total bilirubin\>2×ULN
• ALT or AST\>3 × ULN and total bilirubin\>2xULN or INR \>1.5 17. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP3A4 :
• Itraconazole,
• Ketoconazole,
• Azamulin,
• Troleandomycin,
• Verapamil,
• John's wart,
• Phenobarbital, 18. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2C19:
• Nootkatone,
• Ticlopidine,
• Rifampin,
• Omeprazole), 19. Subjects taking prescription or non-prescription medication which are substrates of CYP2C8:
• Montelukast,
• Quercetin,
• Phenelzine,
• Rifampin,
• Clopidogrel) , 20. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates ofCYP2C9:
• Sulfaphenazole,
• Tienilic acid,
• Carbamazepine,
• Apalutamide,
• Fluconazole,
• Celecoxib 21. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP1A2:
• alpha-Naphthoflavone,
• Furafylline,
• Phenytoin,
• Rifampin,
• Ritonavir,
• smoking,
• Teriflunomide,
• Ciproflaoxacin,
• oral contraceptives,
• Allopurinol 22. Participants within 14 days of the study procedure taking prescription or non-prescription medication which are substrates of CYP2B6:
• Sertraline,
• Phencyclidine,
• Thiotepa,
• Ticlopidine,
• Carbamazepine,
• Efavirenez,
• Rifampin,
• Bupropion.